The discovery of finger loop inhibitors of the hepatitis C virus NS5B polymerase: status and prospects for novel HCV therapeutics.
Millions of people worldwide are infected with the hepatitis C virus (HCV), for which the main current therapy is associated with severe side effects, limited efficacy, is contraindicated in many patients, and has issues of compliance. As a result, new HCV therapies that are more effective and better tolerated are required. This review describes the discovery of a new class of allosteric, non-nucleoside HCV polymerase inhibitors that demonstrate potential for the development of novel anti-HCV therapeutics.